Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2014-06-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes
NCT03452605
Cacao Consumption in Patients With Insulin Resistance
NCT03034291
Dark Chocolate and Glucose Levels in Diabetes
NCT04847999
Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes
NCT01886989
The Effects of Cocoa Flavanols on Insulin Resistance in an 'At-risk' Population
NCT01201590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cocoa
3 servings of polyphenol-rich cocoa beverage consumed per day.
Cocoa
Placebo
3 servings of non-cocoa beverage consumed per day.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocoa
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have at least one of the following: 1) impaired fasting glucose (IFG) after an overnight fast with plasma glucose concentration between 100-125 mg/dl, 2) impaired glucose tolerance (IGT) as identified by the standard Oral Glucose Tolerance Test (OGTT) with 2 hour plasma glucose concentration between 140-200 mg/dl following 75 g glucose OGTT, 3) HbA1c levels between 5.7-6.4% or 4) considered at risk to developing type 2 diabetes by the American Diabetes Association risk assessment. If subjects are above the prediabetic range for any of these tests (indicating they may be type 2 diabetic), they will be excluded and referred to their physician.
* Weight stable (+/-2 kg) for the last 6 months.
* Sedentary to recreationally active (less than 2 d/wk, 20 min/d).
* Have a blood pressure that is less than 160/100 mmHg, total cholesterol that is less than 300 mg/dl and a triglyceride concentration of less than 450 mg/dl.
Exclusion Criteria
* Past or current history of gastrointestinal disorders (including lactose intolerance, ulcers, cancer (stomach, intestinal, colon, pancreatic, liver, etc) NASH, NAFLD, cirrhosis, IBD/IBS, celiac disease, etc).
* Current use of any medication including but not limited to cholesterol lowering medication (including fibric acid derivatives and niacin), antibiotics, immunosuppressive drugs, azole antifungals, non-steroidal anti-inflammatory drugs (NSAIDs), hormone replacement therapy or antioxidants/supplements.
* Use of antibiotics, prebiotics, or probiotics within the prior 3 months.
* Smoking or other tobacco use
* Habitual consumption of alcohol more than 2 servings/d for males and 1 serving/d for females.
* Strict vegetarians or vegans, or strong aversions to major food groups that may be part of the controlled diet.
* Recent surgery
* History of alcohol or drug abuse.
* Pregnant or plan to become pregnant
* Allergic to either lidocaine or bupivacaine
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Hershey Company
INDUSTRY
Virginia Polytechnic Institute and State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrew P. Neilson
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew P Neilson, PhD
Role: PRINCIPAL_INVESTIGATOR
Virginia Polytechnic Institute and State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Human Integrative Physiology Laboratory
Blacksburg, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VT13261005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.